CR20230183A - Proceso para la preparación de compuestos de biheteroarilo y formas cristalinas de estos - Google Patents
Proceso para la preparación de compuestos de biheteroarilo y formas cristalinas de estosInfo
- Publication number
- CR20230183A CR20230183A CR20230183A CR20230183A CR20230183A CR 20230183 A CR20230183 A CR 20230183A CR 20230183 A CR20230183 A CR 20230183A CR 20230183 A CR20230183 A CR 20230183A CR 20230183 A CR20230183 A CR 20230183A
- Authority
- CR
- Costa Rica
- Prior art keywords
- certain
- steps
- biheteroaryl
- elimination
- need
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical group 0.000 title abstract 3
- 239000013078 crystal Chemical group 0.000 title 1
- 239000003054 catalyst Substances 0.000 abstract 2
- 230000008030 elimination Effects 0.000 abstract 2
- 238000003379 elimination reaction Methods 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 2
- 230000003000 nontoxic effect Effects 0.000 abstract 2
- 239000000376 reactant Substances 0.000 abstract 2
- SKMKJBYBPYBDMN-RYUDHWBXSA-N 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine Chemical compound C1=C(OC(F)F)C(N)=NC=C1C1=CC(N2[C@H]3C[C@H](OC3)C2)=NC(N2CC(F)(F)CC2)=N1 SKMKJBYBPYBDMN-RYUDHWBXSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000011097 chromatography purification Methods 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000010970 precious metal Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 229910052723 transition metal Inorganic materials 0.000 abstract 1
- 150000003624 transition metals Chemical class 0.000 abstract 1
- 239000002699 waste material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Catalysts (AREA)
Abstract
Se proporcionan procesos para preparar compuestos de biheteroarilo, incluso el compuesto de biheteroarilo 3-(difluorometoxi)-5-[2-(3,3-difluoropirrolidin-1-il)-6-[(1S,4S)-2-oxa-5-azabiciclo[2.2.1]heptan-5-il]pirimidin-4-il]piridin-2-amina. Entre otras ventajas, los procesos proporcionan: el uso de solventes que son relativamente no tóxicos y asequibles; el uso reducido de catalizadores de metales preciosos costosos; la reducción de la temperatura de reacción en ciertas etapas; el uso de agentes de oxidación relativamente no tóxicos; el uso de catalizadores de metales de transición asequibles; una reducción de las relaciones molares de ciertos reactivos, lo cual mejora la eficiencia del proceso y reduce los costos y desechos; concentraciones de reactivos significativamente más altas en ciertas etapas; eliminación de la necesidad de múltiples etapas de purificación cromatográfica; eliminación de la necesidad de ciertas etapas de extracción mediante el uso de solvente orgánico; y proporcionan un mayor rendimiento y una pureza mejorada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063087109P | 2020-10-02 | 2020-10-02 | |
PCT/US2021/053005 WO2022072721A1 (en) | 2020-10-02 | 2021-09-30 | Process for the preparation of biheteroaryl compounds and crystal forms thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230183A true CR20230183A (es) | 2023-06-14 |
Family
ID=78599176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230183A CR20230183A (es) | 2020-10-02 | 2021-09-30 | Proceso para la preparación de compuestos de biheteroarilo y formas cristalinas de estos |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230312473A1 (es) |
EP (1) | EP4222154A1 (es) |
JP (1) | JP2023544037A (es) |
KR (1) | KR20230079123A (es) |
CN (1) | CN116744933A (es) |
AU (1) | AU2021353532A1 (es) |
BR (1) | BR112023005853A2 (es) |
CA (1) | CA3200566A1 (es) |
CL (1) | CL2023000945A1 (es) |
CR (1) | CR20230183A (es) |
IL (1) | IL301266A (es) |
MX (1) | MX2023003759A (es) |
PE (1) | PE20230781A1 (es) |
WO (1) | WO2022072721A1 (es) |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
CA2450073C (en) | 2001-07-25 | 2017-08-29 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
CN101284136A (zh) | 2002-12-03 | 2008-10-15 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
BR112012009257A2 (pt) | 2009-10-22 | 2016-11-22 | Genentech Inc | modulação de degeneração de axônio. |
MA48577A1 (fr) * | 2013-05-01 | 2021-03-31 | Hoffmann La Roche | Composes biheteroaryle et leurs utilisations |
-
2021
- 2021-09-30 AU AU2021353532A patent/AU2021353532A1/en active Pending
- 2021-09-30 MX MX2023003759A patent/MX2023003759A/es unknown
- 2021-09-30 WO PCT/US2021/053005 patent/WO2022072721A1/en active Application Filing
- 2021-09-30 CN CN202180067829.1A patent/CN116744933A/zh active Pending
- 2021-09-30 PE PE2023001333A patent/PE20230781A1/es unknown
- 2021-09-30 CA CA3200566A patent/CA3200566A1/en active Pending
- 2021-09-30 CR CR20230183A patent/CR20230183A/es unknown
- 2021-09-30 EP EP21806494.7A patent/EP4222154A1/en active Pending
- 2021-09-30 BR BR112023005853A patent/BR112023005853A2/pt unknown
- 2021-09-30 IL IL301266A patent/IL301266A/en unknown
- 2021-09-30 KR KR1020237013971A patent/KR20230079123A/ko unknown
- 2021-09-30 JP JP2023520162A patent/JP2023544037A/ja active Pending
-
2023
- 2023-03-30 CL CL2023000945A patent/CL2023000945A1/es unknown
- 2023-03-31 US US18/194,423 patent/US20230312473A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2023003759A (es) | 2023-04-24 |
JP2023544037A (ja) | 2023-10-19 |
CN116744933A (zh) | 2023-09-12 |
WO2022072721A1 (en) | 2022-04-07 |
IL301266A (en) | 2023-05-01 |
CA3200566A1 (en) | 2022-04-07 |
CL2023000945A1 (es) | 2023-09-29 |
KR20230079123A (ko) | 2023-06-05 |
BR112023005853A2 (pt) | 2023-05-02 |
AU2021353532A1 (en) | 2023-04-13 |
US20230312473A1 (en) | 2023-10-05 |
AU2021353532A8 (en) | 2023-05-04 |
PE20230781A1 (es) | 2023-05-09 |
EP4222154A1 (en) | 2023-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Murai et al. | Asymmetric bromolactonization catalyzed by a C3-symmetric chiral trisimidazoline. | |
Sugimura et al. | Diastereo-differentiating simmons-smith reaction using 2, 4-pentanediol as a chiral auxiliary | |
Yorimitsu et al. | Radical reaction by a combination of phosphinic acid and a base in aqueous media | |
CN107530322B (zh) | 斑螯素和生物活性斑螯素衍生物的商业上可行的合成 | |
WO2006052688A3 (en) | Catalyst and process for the metathesis of ethylene and butene to produce propylene | |
PL2125821T3 (pl) | Sposób wytwarzania sildenafilu | |
CR20230183A (es) | Proceso para la preparación de compuestos de biheteroarilo y formas cristalinas de estos | |
EP1113001A3 (en) | Process for producing nitrile compounds | |
RU2689126C2 (ru) | Способ получения 3-метил-2-нитробензойной кислоты посредством окисления воздухом | |
Saravanan et al. | Tetraethylammonium tetraselenotungstate: a new and efficient selenium transfer reagent for the chemoselective synthesis of functionalised diselenides | |
CN101100450A (zh) | 乙磺酰基乙腈的制备方法 | |
CN111004198B (zh) | 一种苯并吡喃衍生物的合成方法 | |
Matsuo et al. | Silica-catalyzed carboxylative cyclization of propargylic amines with CO2 | |
CN111978245A (zh) | 一种3-氟-2-异丁基吡啶的制备方法 | |
Chen et al. | Synthetic Studies on d-Biotin, Part 9. An Improved Asymmetric Synthetic Route to d-Biotin via Hoffmann–Roche Lactone–Thiolactone Approach | |
EP1595862A4 (en) | PROCESS FOR PRODUCING IODIC COMPOUNDS AND PROCESS FOR PRODUCING HIGH-PURITY 5-IODO-2-METHILBENZOIC ACID | |
CN110804012A (zh) | 一种还原缩硫醛或缩硫酮脱硫的方法 | |
CN113087669B (zh) | 一种4-氰基-5-溴嘧啶的制备方法 | |
Menicagli et al. | Triisobutylaluminum assisted reductive rearrangement of 2-ethoxy-4-alkyl-2, 3-dihydrofurans | |
CN113999239B (zh) | 一种二氮杂桥化合物的合成方法 | |
CN102718694A (zh) | 3-氰基取代吲哚化合物及其合成方法 | |
JP2014105194A (ja) | 二環式アミン化合物の製造法 | |
Zhu et al. | N-Bromoacetamide-mediated domino cyclization and elimination of homoallylic trichloroacetimidates: a novel approach toward the synthesis of 1-bromo-2-amino-3-butene derivatives | |
CN106928124B (zh) | 沙格列汀中间体的制备方法 | |
ZA200307704B (en) | Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate. |